Leqembi collected sales of 29.6 billion Japanese yen (about $194 million) over the last nine months of 2024, putting it on track to reach a 12-month sales target of 42.5 billion Japanese yen ($279 ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...

Biogen reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected.

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese drugmaker is reworking parts of its operations in the U.S. Eisai plans to ...

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for ...